Advances in Therapy · 2025 · 11 citations · 2 references
MedicineEndocrinologyPharmacologyClinical EpidemiologyNutritional EpidemiologyObesity PreventionAsthma ManagementGlucagon-like Peptide-1 Receptor AgonistsIncretin-based TherapiesPancreatic HormonesWeight LossWeight ManagementControlsGlp-1 Receptor PharmacologyGlucagon Receptor AgonistsGlucagon-like Peptide 1 Receptor AgonismGlucagon-like Peptide 1 SignalingGlucagon-like Peptide-1 Receptor SignalingGlucagon-like PeptidesSmall-molecule Glp-1 Receptor Agonists
To quantify the impact of Glucagon-like peptide1 receptor-agonists (GLP1-RAs) on asthma control, we analysed people with asthma and obesity, using the Optimum Patient Care Research Database (OPCRD). We identified 10,111 GLP1-RA exposed people and 50,555 unexposed controls. The exposed cohort had higher BMI and more uncontrolled asthma [risk domain asthma control (RDAC) and overall asthma control (OAC)]. The exposed cohort lost more weight and had improved asthma control for both RDAC (odds ratio 2.11 95% CI 1.90-2.36) and OAC (OR 2.10, 95%CI 1.81-2.45) scores. GLP1-RA drugs appear to improve asthma control for people with obesity.
2
Gene Colice, Alison Chisholm, Alexandra L. Dima et al. · Pragmatic and Observational Research · 2018 · 22 citations · Full text